Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Dexamethasone
Drug: Prednisone
Drug: Methylprednisolone
Drug: Lenalidomide
Drug: Pomalidomide

First Posted Date: 2014-11-19

Last Posted Date: 2023-11-01

Lead Sponsor: Oncotherapeutics

Target Recruit Count: 45

Registration Number: NCT02294357

Locations: 🇺🇸
James R Berenson, MD, Inc., West Hollywood, California, United States
🇺🇸
Blood & Cancer Center of East Texas, Tyler, Texas, United States
🇺🇸
California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States

and more 4 locations

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

Phase 3

Completed

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: Placebo
Drug: lenalidomide
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: prednisone
Drug: vincristine

First Posted Date: 2014-11-06

Last Posted Date: 2023-06-22

Lead Sponsor: Celgene

Target Recruit Count: 570

Registration Number: NCT02285062

Locations: 🇺🇸
Local Institution - 151, Dallas, Texas, United States
🇺🇸
Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
🇺🇸
Local Institution - 161, Philadelphia, Pennsylvania, United States

and more 155 locations

Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1

Withdrawn

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Small Lymphocytic Lymphoma
B-cell Adult Acute Lymphoblastic Leukemia
Recurrent Grade 3 Follicular Lymphoma
Small Intestine Lymphoma
Testicular Lymphoma

Interventions: Biological: rituximab
Drug: lenalidomide
Drug: romidepsin
Other: laboratory biomarker analysis

First Posted Date: 2014-11-02

Last Posted Date: 2016-08-11

Lead Sponsor: Mayo Clinic

Registration Number: NCT02281279

Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Lenalidomide
Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Cytarabine
Procedure: NK Cells

First Posted Date: 2014-10-31

Last Posted Date: 2023-06-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT02280525

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Phase 2

Completed

Conditions: Smoldering Myeloma
Smoldering Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2014-10-31

Last Posted Date: 2023-06-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 51

Registration Number: NCT02279394

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 6 locations

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Lenalidomide

First Posted Date: 2014-10-31

Last Posted Date: 2022-08-19

Lead Sponsor: Celgene

Target Recruit Count: 389

Registration Number: NCT02279654

Locations: 🇺🇸
Local Institution - 0002, Centre City, New Jersey, United States
🇺🇸
Local Institution - France, No City Provided, New Jersey, United States
🇺🇸
Local Institution - 0001, Centre City, New Jersey, United States

and more 143 locations

Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone
Biological: Elotuzumab (BMS-901608)

First Posted Date: 2014-10-23

Last Posted Date: 2022-06-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 82

Registration Number: NCT02272803

Locations: 🇯🇵
Local Institution, Kasama-shi, Japan

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Phase 1

Terminated

Conditions: Advanced Malignancies
Solid Tumors
Metastatic Cancer

Interventions: Drug: azacitidine
Drug: gemcitabine
Drug: INCB052793
Drug: nab-paclitaxel
Drug: INCB039110
Drug: dexamethasone
Drug: Carfilzomib
Drug: bortezomib
Drug: lenalidomide
Drug: pomalidomide
Drug: INCB050465

First Posted Date: 2014-10-16

Last Posted Date: 2020-04-17

Lead Sponsor: Incyte Corporation

Target Recruit Count: 83

Registration Number: NCT02265510

Locations: 🇺🇸
Site 2, Nashville, Tennessee, United States

Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia (AML)
Acute Myelocytic Leukemia
Acute Non-Lymphocytic Leukemia
Acute Myelogenous Leukemia
Acute Granulocytic Leukemia

Interventions: Drug: Lenalidomide
Genetic: HLA-mismatched stem-cell Microtransplantation
Drug: Cytarabine

First Posted Date: 2014-10-02

Last Posted Date: 2017-08-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 8

Registration Number: NCT02255162

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Biological: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2014-10-01

Last Posted Date: 2024-10-01

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 236

Registration Number: NCT02253316

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy